AASLD News
AASLD Announces the Liver Network of Excellence, a New National Initiative to Transform Liver Care
Unveiled at The Liver Meeting ®, the initiative will bring liver care teams together to share expertise, advance best practices, and improve patient outcomes nationwide. DENVER, Co. — Nov. 6, 2026 — The American Association for the Study of Liver Diseases (AASLD) announced the launch of the Liver Network of Excellence, a new national initiative designed to transform liver care by connecting
AASLD Publishes Second Expert-Based Practice Opinion (EXPO), Addressing Diagnosis and Management of Hepatitis Delta Virus Infection
New EXPO published in HEPATOLOGY provides timely, practical recommendations for HDV screening, diagnosis, monitoring and treatment amid advances in antiviral therapy. DENVER (Nov. 6, 2026) — The American Association for the Study of Liver Diseases (AASLD) today announced the publication of its second Expert-Based Practice Opinion (EXPO), AASLD Expert-Based Practice Opinion (EXPO): Diagnosis and
Phase III ELSPIRE Trial Results Published in HEPATOLOGY Demonstrates Elafibranor Achieves ALP Normalization in More Than 85% of Patients with Primary Biliary Cholangitis
Elafibranor significantly improved key markers of disease activity compared with placebo, supporting ALP normalization as an achievable treatment goal for patients with PBC who have an incomplete response or intolerance to first-line therapy. ALEXANDRIA, Va. — Nov. 5, 2026 — The American Association for the Study of Liver Diseases (AASLD) today announced the publication of positive Phase III
Hepatitis B and MASH Lead Late-Breaking Research at The Liver Meeting® 2026
Forty-two abstracts include late-stage trials, early-phase RNA editing, and new research across liver disease DENVER (Nov. 5, 2026) — The American Association for the Study of Liver Diseases (AASLD) announced 42 late-breaking research abstracts to be presented at The Liver Meeting ® (TLM) 2026. The meeting opens today at the Colorado Convention Center in Denver and runs through Nov. 9. Hepatitis B
AASLD Joins Global Liver Societies to Establish Unified Definition of Acute-on-Chronic Liver Failure
Published in HEPATOLOGY , this international consensus aims to improve diagnosis, patient care and clinical research worldwide. ALEXANDRIA, Va. – Oct. 30 – The American Association for the Study of Liver Diseases (AASLD), in collaboration with four leading international liver societies, developed a unified global framework for defining and managing acute-on-chronic liver failure (ACLF), a life
AASLD and AGA Offer First Medication-focused Guideline for Treating PBC
Peroxisome proliferator-activated receptor agonists are suggested as second-line therapy for patients with primary biliary cholangitis (PBC) who do not respond adequately to or are intolerant of ursodeoxycholic acid. Bethesda, MD and Alexandria, VA (Oct. 22, 2026) — For the first time, a joint guideline from the American Association for the Study of Liver Diseases (AASLD) and the American
HEPATOLOGY Achieves Highest-Ever Impact Factor
Record 21.3 Impact Factor reinforces the journal’s global leadership in advancing liver research and clinical care. ALEXANDRIA, Va. — October 15, 2026 — The American Association for the Study of Liver Diseases (AASLD) today announced that its flagship journal, HEPATOLOGY, has achieved a 2025 Impact Factor of 21.3, according to the latest Journal Citation Reports™. This milestone reflects the
AASLD Publishes First Expert-Based Practice Opinion (EXPO) on Liver Biopsy
A new approach to timely clinical guidance, EXPOs combine targeted evidence review with expert interpretation and consensus to support informed clinical decision-making. ALEXANDRIA, Va., Oct.15, 2026 — The American Association for the Study of Liver Diseases (AASLD) today announced the publication of its first-ever Expert-Based Practice Opinion (EXPO), marking the launch of a new type of clinical
AASLD Announces Results of 2027 General Election
AASLD members elect new leaders to help shape the association’s future and advance hepatology. ALEXANDRIA, Va. (October 14, 2026) — The American Association for the Study of Liver Diseases (AASLD) today announced the results of its 2027 General Election, welcoming three newly elected leaders who will help guide the association and support its mission to advance and disseminate the science and
AASLD Leads With the Latest in Liver Cancer Research and Care
This Liver Cancer Awareness Month, AASLD spotlights an open access HEPATOLOGY special issue and resources advancing evidence-based care. ALEXANDRIA, Va. (October 6, 2026) — In recognition of Liver Cancer Awareness Month this October, the American Association for the Study of Liver Diseases (AASLD) is elevating new research, clinical guidance, and educational resources aimed at advancing the
AASLD Lifts Press Embargo for The Liver Meeting® 2026 Abstracts
Alexandria, Va. (Oct. 5, 2026) Today the American Association for the Study of Liver Diseases (AASLD) lifted the press embargo on abstracts submitted for The Liver Meeting® (TLM), Denver. Over 2,900 abstracts have been submitted to date. Within the submissions, topics cover 24 different topic areas including MASLD, Liver Transplantation, Liver Surgery, and Hepatitis B. The supplement provides the
Announcing the Inaugural AASLD Impact Award Recipients
New award recognizes rising leaders shaping the future of hepatology through innovation, leadership, and service. ALEXANDRIA, Va. — August 13, 2026 — The American Association for the Study of Liver Diseases (AASLD) is proud to announce the inaugural recipients of the AASLD Impact Award, a new professional recognition award celebrating mid-career members who are making significant contributions
HEPATOLOGY Publishes Landmark North American Framework to Advance Treatment Decisions for Liver Cancer
New multidisciplinary framework helps clinicians navigate today's expanding treatment landscape for hepatocellular carcinoma. ALEXANDRIA, Virginia (August 7, 2026) — The American Association for the Study of Liver Diseases (AASLD) announces the publication of BEACON-HCC, a landmark multidisciplinary consensus now available online in HEPATOLOGY, the premier journal in liver disease. Developed by 20
AASLD Unveils New People Affected by Liver Disease Travel Award for The Liver Meeting® 2026, Denver
This travel award provides access for people with liver disease to liver disease education, emerging research, and engagement opportunities, with a focus on individuals affected by Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Alexandria, VA – July 13, 2026 – The American Association for the Study of Liver Diseases (AASLD) proudly announces the new People Affected by Liver